Arecor, a company focused on the development and delivery of novel therapeutics for diabetes and other cardiometabolic diseases, today announced a significant strengthening of its intellectual property (IP) portfolio. The company has secured a U.S. patent grant and received approval for a European patent to protect its lead programme, AT278, while also filing a new patent application related to its innovative oral peptide delivery technology. We view the grant as an important event, validating AREC’s leadership in developing next-gen insulins and positioning AT278 as a disruptor technology. The new patents add to a robust global intellectual property portfolio of the Company protecting AT278 and the Arestat® technology, and follow a number of additional patents already granted in major territories. BUY.
